CoChat
Sign Up
Cited by 898Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphismsCholesterol and Lipid Metabolism

Molecular Actions of PPARα in Lipid Metabolism and Inflammation

Open access
Bougarne, Nadia, Weyers, Basiel, Desmet, Sofie J, Deckers, Julie, Ray, David W, Staels, Bart, De Bosscher, Karolien·2018·Endocrine Reviews
DOI 10.1210/er.2018-00064
Open this paper in CoChat — free accountOpen PDF

Abstract

Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first-generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in, and ill-designed cardiovascular intervention trials. Notwithstanding, understanding the molecular mechanisms by which PPARα works will enable control of its activities as a drug target for metabolic diseases with an underlying inflammatory component. Given its role in reshaping the immune system, the full potential of this nuclear receptor subtype as a versatile drug target with high plasticity becomes increasingly clear, and a novel generation of agonists may pave the way for novel fields of applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2018-00064

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is no solid evidence from liver imaging and/or histology for a beneficial effect of metformin on MASLD components in clinical studies.

    “there is no solid evidence from liver imaging and/or histology in regards to a beneficial effect of metformin on MASLD components in clinical studies [168,169].”

    From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [169]

    The passages on human clinical trials discuss PPARα agonists, including fenofibrate and elafibranor, rather than metformin. A search of our copy for metformin found no passage assessing its effects on fatty liver disease by imaging or histology, so this source does not verify the attributed claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 116

  1. Chen F, Law SW, O'Malley BW. Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun. 1993;196(2):671-677.
  2. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta- oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68(5):879-887.
  3. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996;12(1):335-363.
  4. Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol. 2004;18(6):1321-1332.
  5. Poulsen Ll, Siersbæk M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol. 2012;23(6):631-639.
  6. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxi- some proliferators. Nature. 1990;347(6294):645-650.
  7. Islinger M, Cardoso MJ, Schrader M. Be different- the diversity of peroxisomes in the animal king- dom. Biochim Biophys Acta. 2010;1803(8): 881-897.
  8. Kersten S. Integrated physiology and systems bi- ology of PPARa. Mol Metab. 2014;3(4):354-371.
  9. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994;91(15): 7355-7359.
  10. Escher P, Wahli W. Peroxisome proliferator- activated receptors: insight into multiple cellular functions. Mutat Res. 2000;448(2):121-138.
  11. Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors: shifting endocrinology into re- verse. Science. 1999;284(5415):757-760.
  12. Schupp M, Lazar MA. Endogenous ligands for nu- clear receptors: digging deeper. J Biol Chem. 2010; 285(52):40409-40415.
  13. Barbier O, Fontaine C, Fruchart JC, Staels B. Genomic and non-genomic interactions of PPARa with xenobiotic-metabolizing enzymes. Trends Endo- crinol Metab. 2004;15(7):324-330.
  14. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of per- oxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22(5):717-726.
  15. Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci. 2002; 967(1):7-18.
  16. Etgen GJ, Mantlo N. PPAR ligands for metabolic disorders. Curr Top Med Chem. 2003;3(14): 1649-1661.
  17. Lee WS, Kim J. Peroxisome proliferator-activated receptors and the heart: lessons from the past and future directions. PPAR Res. 2015;2015:271983.
  18. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Phar- macol. 2000;129(5):823-834.
  19. Jiang C, Ting AT, Seed B. PPAR-g agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82-86.
  20. Ren B, Thelen A, Jump DB. Peroxisome proliferator- activated receptor alpha inhibits hepatic S14 gene transcription. Evidence against the peroxisome proliferator-activated receptor alpha as the medi- ator of polyunsaturated fatty acid regulation of S14 gene transcription. J Biol Chem. 1996;271(29): 17167-17173.
  21. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators. Nature. 1998;393(6687):790-793.
  22. Chinetti G, Fruchart J, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid meta- bolism and inflammation. Inflamm Res. 2000;49(30): 497-505.
  23. Kersten S, Stienstra R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie. 2017;136:75-84.
  24. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116(3): 571-580.
  25. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARa: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002.
  26. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal. 2009;11(6):1415-1452.
  27. Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, Desvergne B. Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator- activated receptor/retinoid X receptor hetero- dimers in the absence and presence of ligand. J Biol Chem. 2005;280(18):17880-17890.
  28. Bordji K, Grillasca JP, Gouze JN, Magdalou J, Schohn H, Keller JM, Bianchi A, Dauça M, Netter P, Terlain B. Evidence for the presence of peroxisome proliferator- activated receptor (PPAR) a and g and retinoid Z receptor in cartilage. PPARg activation modulates the effects of interleukin-1b on rat chondrocytes. J Biol Chem. 2000;275(16):12243-12250.
  29. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated re- ceptors a and g induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998; 273(40):25573-25580.
  30. Umemoto T, Fujiki Y. Ligand-dependent nucleo- cytoplasmic shuttling of peroxisome proliferator- activated receptors, PPARa and PPARg. Genes Cells. 2012;17(7):576-596.
  31. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor g. Mol Cell Biol. 2007; 27(3):803-817.
  32. Desvergne B, Wahli W. Peroxisome proliferator- activated receptors: nuclear control of meta- bolism. Endocr Rev. 1999;20(5):649-688.
  33. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome pro- liferator activated receptor. Biochemistry. 1993; 32(21):5598-5604.
  34. Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde G, Cellier C, Faith JM, Després JP, Morgan K, Hudson TJ. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res. 2000;41(6):945-952.
  35. Bugge A, Mandrup S. Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation. PPAR Res. 2010;2010:169506.
  36. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjöblom K, Karlsson U, Lindstedt EL, Bamberg K. Structure of the PPARa and -g ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure. 2001;9(8):699-706.
  37. Hi R, Osada S, Yumoto N, Osumi T. Character- ization of the amino-terminal activation domain of peroxisome proliferator-activated receptor a. Im- portance of alpha-helical structure in the trans- activating function. J Biol Chem. 1999;274(49): 35152-35158.
  38. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptor a (PPARa) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem. 2002;277(40): 37254-37259.
  39. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta. 2007;1771(8):952-960.
  40. Diradourian C, Girard J, Pégorier JP. Phosphorylation of PPARs: from molecular characterization to phys- iological relevance. Biochimie. 2005;87(1):33-38.
  41. Castillo G, Brun RP, Rosenfield JK, Hauser S, Park CW, Troy AE, Wright ME, Spiegelman BM. An adipogenic cofactor bound by the differentia- tion domain of PPARg. EMBO J. 1999;18(13): 3676-3687.
  42. Hsu MH, Palmer CN, Song W, Griffin KJ, Johnson EF. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J Biol Chem. 1998;273(43):27988-27997.
  43. Gray JP, Burns KA, Leas TL, Perdew GH, Vanden Heuvel JP. Regulation of peroxisome proliferator- activated receptor a by protein kinase C. Bio- chemistry. 2005;44(30):10313-10321.
  44. Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Naj ïb J, Laudet V, Staels B. Fibrates increase human REV-ERBa expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol. 1999; 13(3):400-409.
  45. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Cir- culation. 1998;98(19):2088-2093.
  46. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358(6389):771-774.
  47. Gervois P, Torra IP, Chinetti G, Grötzinger T, Dubois G, Fruchart JC, Fruchart-Najib J, Leitersdorf E, Staels B. A truncated human peroxisome proliferator- activated receptor a splice variant with domi- nant negative activity. Mol Endocrinol. 1999;13(9): 1535-1549.
  48. Dowell P, Peterson VJ, Zabriskie TM, Leid M. Ligand- induced peroxisome proliferator-activated receptor a conformational change. J Biol Chem. 1997;272(3): 2013-2020.
  49. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor a. Mol Endocrinol. 2004;18(8):1906-1918.
  50. Pourcet B, Pineda-Torra I, Derudas B, Staels B, Glineur C. SUMOylation of human peroxisome proliferator-activated receptor a inhibits its trans- activity through the recruitment of the nu- clear corepressor NCoR. J Biol Chem. 2010;285(9): 5983-5992.
  51. Sumanasekera WK, Tien ES, Davis JW II, Turpey R, Perdew GH, Vanden Heuvel JP. Heat shock protein- 90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-a (PPARa) and PPARb activity. Biochemistry. 2003;42(36):10726-10735.
  52. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated re- ceptors. Proc Natl Acad Sci USA. 2001;98(24): 13919-13924.
  53. Leuenberger N, Pradervand S, Wahli W. Sumoylated PPARa mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. J Clin Invest. 2009;119(10):3138-3148.
  54. Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG, Meier CA. Peroxisome proliferator-activated receptor medi- ates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat. J Biol Chem. 1995;270(30):18117-18122.
  55. Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, Pernin A, Takeshita A, Chin WW, Burger AG, Meier CA. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor a by phosphorylation of a ligand-independent trans- activating domain. J Biol Chem. 1999;274(15): 10505-10510.
  56. Benson S, Padmanabhan S, Kurtz TW, Pershadsingh HA. Ligands for the peroxisome proliferator- activated receptor-g and the retinoid X receptor- a exert synergistic antiproliferative effects on human coronary artery smooth muscle cells. Mol Cell Biol Res Commun. 2000;3(3):159-164.
  57. Cha BS, Ciaraldi TP, Carter L, Nikoulina SE, Mudaliar S, Mukherjee R, Paterniti JR Jr, Henry RR. Peroxisome proliferator-activated receptor (PPAR) g and reti- noid X receptor (RXR) agonists have comple- mentary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia. 2001;44(4): 444-452.
  58. Desvergne B. RXR: from partnership to leadership in metabolic regulations. Vitam Horm. 2007;75:1-32.
  59. Schulman IG, Shao G, Heyman RA. Transactivation by retinoid X receptor-peroxisome proliferator- activated receptor g (PPARg) heterodimers: in- termolecular synergy requires only the PPARg hormone-dependent activation function. Mol Cell Biol. 1998;18(6):3483-3494.
  60. Shimizu M, Moriwaki H. Synergistic effects of PPARg ligands and retinoids in cancer treatment. PPAR Res. 2008;2008:181047.
  61. Yamamoto A, Kakuta H, Miyachi H, Sugimoto Y. Involvement of the retinoid X receptor ligand in the anti-inflammatory effect induced by peroxisome proliferator-activated receptor g agonist in vivo. PPAR Res. 2011;2011:840194.
  62. IJpenberg A, Jeannin E, Wahli W, Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/ retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem. 1997;272(32): 20108-20117.
  63. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear re- ceptors. Nature. 2008;454(7203):470-477.
  64. DiRenzo J, Söderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Hörlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator-activated re- ceptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and co- repressors. Mol Cell Biol. 1997;17(4):2166-2176.
  65. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M. Identification of nuclear receptor co- repressor as a peroxisome proliferator-activated receptor a interacting protein. J Biol Chem. 1999; 274(22):15901-15907.
  66. van der Meer DL, Degenhardt T, Väisänen S, de Groot PJ, Heinäniemi M, de Vries SC, Müller M, Carlberg C, Kersten S. Profiling of promoter oc- cupancy by PPARa in human hepatoma cells via ChIP-chip analysis. Nucleic Acids Res. 2010;38(9): 2839-2850.
  67. Boergesen M, Pedersen TA, Gross B, van Heeringen SJ, Hagenbeek D, Bindesbøll C, Caron S, Lalloyer F, Steffensen KR, Nebb HI, Gustafsson JA, Stunnenberg HG, Staels B, Mandrup S. Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor a in mouse liver re- veals extensive sharing of binding sites. Mol Cell Biol. 2012;32(4):852-867.
  68. Sarusi Portuguez A, Schwartz M, Siersbaek R, Nielsen R, Sung MH, Mandrup S, Kaplan T, Hakim O. Hierarchical role for transcription factors and chromatin structure in genome organization along adipogenesis. FEBS J. 2017;284(19):3230-3244.
  69. Siersbæk R, Nielsen R, John S, Sung MH, Baek S, Loft A, Hager GL, Mandrup S. Extensive chromatin remodelling and establishment of transcription factor "hotspots" during early adipogenesis. EMBO J. 2011;30(8):1459-1472.
  70. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. Structure of the intact PPAR-g-RXR-a nuclear receptor complex on DNA. Nature. 2008;456(7220):350-356.
  71. R} oszer T, Menéndez-Gutiérrez MP, Cedenilla M, Ricote M. Retinoid X receptors in macrophage biology. Trends Endocrinol Metab. 2013;24(9): 460-468.
  72. Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) a and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endo- crinol. 2003;17(7):1255-1267.
  73. Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Yatoh S, Kitamine T, Okazaki H, Tamura Y, Sekiya M, Takahashi A, Hasty AH, Sato R, Sone H, Osuga J, Ishibashi S, Yamada N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) a and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol. 2003; 17(7):1240-1254.
  74. Hashimoto K, Cohen RN, Yamada M, Markan KR, Monden T, Satoh T, Mori M, Wondisford FE. Cross- talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thy- roid hormone resistance mouse model. J Biol Chem. 2006;281(1):295-302.
  75. Oka S, Zhai P, Yamamoto T, Ikeda Y, Byun J, Hsu CP, Sadoshima J. Peroxisome proliferator activated re- ceptor-a association with silent information reg- ulator 1 suppresses cardiac fatty acid metabolism in the failing heart. Circ Heart Fail. 2015;8(6):1123-1132.
  76. Oka S, Alcendor R, Zhai P, Park JY, Shao D, Cho J, Yamamoto T, Tian B, Sadoshima J. PPARa-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab. 2011;14(5):598-611.
  77. Oka S, Zhai P, Alcendor R, Park JY, Tian B, Sadoshima J. Suppression of ERR targets by a PPARa/Sirt1 complex in the failing heart. Cell Cycle. 2012;11(5):856-864.
  78. Villarroya J, Redondo-Angulo I, Iglesias R, Giralt M, Villarroya F, Planavila A. Sirt1 mediates the effects of a short-term high-fat diet on the heart. J Nutr Biochem. 2015;26(11):1328-1337.
  79. Gray JP, Davis JW 2nd, Gopinathan L, Leas TL, Nugent CA, Vanden Heuvel JP. The ribosomal protein rpL11 associates with and inhibits the transcriptional activity of peroxisome proliferator- activated receptor-a. Toxicol Sci. 2006;89(2): 535-546.
  80. Iwamoto F, Umemoto T, Motojima K, Fujiki Y. Nuclear transport of peroxisome-proliferator acti- vated receptor a. J Biochem. 2011;149(3):311-319.
  81. Rodríguez JE, Liao JY, He J, Schisler JC, Newgard CB, Drujan D, Glass DJ, Frederick CB, Yoder BC, Lalush DS, Patterson C, Willis MS. The ubiquitin ligase MuRF1 regulates PPARa activity in the heart by enhancing nuclear export via monoubiquitination. Mol Cell Endocrinol. 2015;413:36-48.
  82. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARa gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia. 2000;43(5):673-680.
  83. Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, Staels B, Froguel P. Mutation screening of the PPARa gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 2000;26(5):393-401.
  84. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2002;22(5):805-810.
  85. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ. The human per- oxisome proliferator-activated receptor a gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics. 2000; 10(4):321-333.
  86. Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvänne M. Peroxisome proliferator- activated receptor a gene variants influence pro- gression of coronary atherosclerosis and risk of coronary artery disease. Circulation. 2002;105(12): 1440-1445.
  87. Robitaille J, Brouillette C, Houde A, Lemieux S, Pérusse L, Tchernof A, Gaudet D, Vohl MC. Associ- ation between the PPARa-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004;49(9):482-489.
  88. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ, Tucker KL, Ordovas JM; Framingham Heart Study. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III con- centrations in the Framingham Heart Study. J Nutr. 2005;135(3):397-403.
  89. Bossé Y, Després JP, Bouchard C, Pérusse L, Vohl MC. The peroxisome proliferator-activated re- ceptor a L162V mutation is associated with re- duced adiposity. Obes Res. 2003;11(7):809-816.
  90. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the per- oxisome proliferator-activated receptor a (PPARa) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med (Berl). 2001;79(4):198-204.
  91. Gouni-Berthold I, Giannakidou E, Müller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W. As- sociation between the PPARa L162V poly- morphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am Heart J. 2004;147(6):1117-1124.
  92. Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E. Evidence that peroxisome proliferator-activated receptor d influences cho- lesterol metabolism in men. Arterioscler Thromb Vasc Biol. 2003;23(4):637-643.
  93. Bosse Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Despres JP, Vohl MC. Influences of the PPARa-L162V polymorphism on plasma HDL(2)-cholesterol response of abdomi- nally obese men treated with gemfibrozil. Genet Med. 2002;4(4):311-315. 100. Brisson D, Ledoux K, Bossé Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D. Effect of apolipoprotein E, peroxisome proliferator-activated receptor a and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hyper- triglyceridemic patients. Pharmacogenetics. 2002; 12(4):313-320. 101. Paradis AM, Fontaine-Bisson B, Bossé Y, Robitaille J, Lemieux S, Jacques H, Lamarche B, Tchernof A, Couture P, Vohl MC. The peroxisome proliferator- activated receptor a Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am J Clin Nutr. 2005;81(2):523-530. 102. Hara M, Wang X, Paz VP, Iwasaki N, Honda M, Iwamoto Y, Bell GI. Identification of three missense mutations in the peroxisome proliferator-activated receptor a gene in Japanese subjects with maturity- onset diabetes of the young. J Hum Genet. 2001; 46(5):285-288. 103. Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH, Kim H, Aoyama T, Gonzalez FJ, Nakajima T. Association of V227A PPARa polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmaco- genet Genomics. 2006;16(8):569-577. 104. Yamakawa-Kobayashi K, Ishiguro H, Arinami T, Miyazaki R, Hamaguchi H. A Val227Ala poly- morphism in the peroxisome proliferator activated receptor a (PPARa) gene is associated with vari- ations in serum lipid levels. J Med Genet. 2002;39(3): 189-191. 105. Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis. 2006;187(2):309-315. 106. Liu MH, Li J, Shen P, Husna B, Tai ES, Yong EL. A natural polymorphism in peroxisome proliferator- activated receptor-a hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin. Mol Endo- crinol. 2008;22(5):1078-1092. 107. Chen S, Li Y, Li S, Yu C. A Val227Ala substitution in the peroxisome proliferator activated receptor al- pha (PPAR alpha) gene associated with non- alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J Gastroenterol Hepatol. 2008;23(9):1415-1418. 108. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-a ex- pression in human liver. Mol Pharmacol. 1998;53(1): 14-22. 109.
  94. Thomas M, Bayha C, Klein K, Müller S, Weiss TS, Schwab M, Zanger UM. The truncated splice var- iant of peroxisome proliferator-activated receptor alpha, PPARa-tr, autonomously regulates pro- liferative and pro-inflammatory genes. BMC Cancer. 2015;15(1):488. 110. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator- activated receptor a mediates the adaptive re- sponse to fasting. J Clin Invest. 1999;103(11): 1489-1498. 111. Pawlak M, Lefebvre P, Staels B. Molecular mecha- nism of PPARa action and its impact on lipid metabolism, inflammation and fibrosis in non- alcoholic fatty liver disease. J Hepatol. 2015;62(3): 720-733. 112. Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem. 2001;276(52):49066-49076. 113. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor a gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the a2 form of AMP-activated protein kinase. Mol Cell Biol. 2007; 27(12):4317-4327. 114. Zhou YT, Shimabukuro M, Wang MY, Lee Y, Higa M, Milburn JL, Newgard CB, Unger RH. Role of peroxisome proliferator-activated receptor a in disease of pancreatic b cells. Proc Natl Acad Sci USA. 1998;95(15):8898-8903. 115. Soukas A, Cohen P, Socci ND, Friedman JM. Leptin- specific patterns of gene expression in white adi- pose tissue. Genes Dev. 2000;14(8):963-980. 116.
  95. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. 2005;42(3):568-577. 117. Carlsson L, Lindén D, Jalouli M, Oscarsson J. Effects of fatty acids and growth hormone on liver fatty acid binding protein and PPARa in rat liver. Am J Physiol Endocrinol Metab. 2001;281(4):E772-E781. 118. Yamada J, Sugiyama H, Watanabe T, Suga T. Sup- pressive effect of growth hormone on the ex- pression of peroxisome proliferator-activated receptor in cultured rat hepatocytes. Res Commun Mol Pathol Pharmacol. 1995;90(1):173-176. 119.
  96. Dunlop TW, Väisänen S, Frank C, Molnár F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor d gene is a primary target of 1a,25-dihydroxyvitamin D 3 and its nuclear receptor. J Mol Biol. 2005;349(2):248-260. 143. White JH, Fernandes I, Mader S, Yang XJ. Co- repressor recruitment by agonist-bound nuclear receptors. Vitam Horm. 2004;68:123-143. 144. Leonardsson G, Steel JH, Christian M, Pocock V, Milligan S, Bell J, So PW, Medina-Gomez G, Vidal- Puig A, White R, Parker MG. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc Natl Acad Sci USA. 2004;101(22):8437-8442. 145.
  97. Vanden Heuvel JP, Kreder D, Belda B, Hannon DB, Nugent CA, Burns KA, Taylor MJ. Comprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome pro- liferator WY14,643. Toxicol Appl Pharmacol. 2003; 188(3):185-198. 156. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B. Acute antiin- flammatory properties of statins involve peroxisome proliferator-activated receptor-a via inhibition of the protein kinase C signaling pathway. Circ Res. 2006; 98(3):361-369. 157. Joly E, Roduit R, Peyot ML, Habinowski SA, Ruderman NB, Witters LA, Prentki M. Glucose re- presses PPARa gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic b-cell. J Diabetes. 2009;1(4):263-272. 158. Ravnskjaer K, Boergesen M, Dalgaard LT, Mandrup S. Glucose-induced repression of PPARa gene ex- pression in pancreatic beta-cells involves PP2A activation and AMPK inactivation. J Mol Endocrinol. 2006;36(2):289-299. 159. Ratman D, Mylka V, Bougarne N, Pawlak M, Caron S, Hennuyer N, Paumelle R, De Cauwer L, Thommis J, Rider MH, Libert C, Lievens S, Tavernier J, Staels B, De Bosscher K. Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARa. Nucleic Acids Res. 2016;44(22): 10539-10553. 160
  98. Blanquart C, Mansouri R, Fruchart JC, Staels B, Glineur C. Different ways to regulate the PPARa stability. Biochem Biophys Res Commun. 2004; 319(2):663-670. 161. Gopinathan L, Hannon DB, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator- activated receptor-alpha by MDM2. Toxicol Sci. 2009;108(1):48-58. 162. Hinds TD Jr, Burns KA, Hosick PA, McBeth L, Nestor- Kalinoski A, Drummond HA, AlAmodi AA, Hankins MW, Vanden Heuvel JP, Stec DE. Biliverdin re- ductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3b phosphor- ylation of serine 73 of peroxisome proliferator- activated receptor (PPAR) a. J Biol Chem. 2016; 291(48):25179-25191. 163. Wadosky KM, Willis MS. The story so far: post- translational regulation of peroxisome proliferator- activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol. 2012; 302(3):H515-H526. 164. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARa-leukotriene B 4 pathway to inflammation control. Nature. 1996; 384(6604):39-43. 165. Hostetler HA, Petrescu AD, Kier AB, Schroeder F. Peroxisome proliferator-activated receptor a in- teracts with high affinity and is conformationally responsive to endogenous ligands. J Biol Chem. 2005; 280(19):18667-18682. 166.
  99. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B. Oxidized phospholipids activate PPARa in a phospholipase A2-dependent manner. FEBS Lett. 2000;471(1):34-38. 174. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPARa in liver. Cell. 2009;138(3):476-488. 175. Esposito E, Mazzon E, Paterniti I, Dal Toso R, Pressi G, Caminiti R, Cuzzocrea S. PPAR-a contributes to the anti-inflammatory activity of verbascoside in a model of inflammatory bowel disease in mice. PPAR Res. 2010;2010:917312. 176. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor a in mice. Neurosci Lett. 2003;352(3):203-206. 177. Radler U, Stangl H, Lechner S, Lienbacher G, Krepp R, Zeller E, Brachinger M, Eller-Berndl D, Fischer A, Anzur C, Schoerg G, Mascher D, Laschan C, Anderwald C, Lohninger A. A combination of (v-3) polyunsaturated fatty acids, polyphenols and L- carnitine reduces the plasma lipid levels and in- creases the expression of genes involved in fatty acid oxidation in human peripheral blood mono- nuclear cells and HepG2 cells. Ann Nutr Metab. 2011;58(2):133-140. 178. Tsukamoto T, Nakata R, Tamura E, Kosuge Y, Kariya A, Katsukawa M, Mishima S, Ito T, Iinuma M, Akao Y, Nozawa Y, Arai Y, Namura S, Inoue H. Vaticanol C, a resveratrol tetramer, activates PPARa and PPARb/d in vitro and in vivo. Nutr Metab (Lond). 2010;7(1):46. 179. Giral H, Villa-Bellosta R, Catalan J, Sorribas V. Cytotoxicity of peroxisome proliferator-activated receptor a and g agonists in renal proximal tubular cell lines. Toxicol In Vitro. 2007;21(6): 1066-1076. 180.
  100. Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. Dual peroxisome proliferator-activated receptor a/d agonist GFT505 improves hepatic and pe- ripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013;36(10):2923-2930. 194.
  101. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated re- ceptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11(6):779-791. 200. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 2005;1(5):309-322. 201. Chakravarthy MV, Zhu Y, López M, Yin L, Wozniak DF, Coleman T, Hu Z, Wolfgang M, Vidal-Puig A, Lane MD, Semenkovich CF. Brain fatty acid synthase activates PPARa to maintain energy homeostasis. J Clin Invest. 2007;117(9):2539-2552. 202. Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 2013;62(7):2164-2172. 203. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators reg- ulate genes governing lipoprotein metabolism, vas- cular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10(3):245-258. 204. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep. 2001;3(1): 83-92. 205. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y. Effects of bezafi- brate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 2001;50(4):477-480. 206. Frohnert BI, Hui TY, Bernlohr DA. Identification of a functional peroxisome proliferator-responsive ele- ment in the murine fatty acid transport protein gene. J Biol Chem. 1999;274(7):3970-3977. 207. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARa and PPARg activators. J Biol Chem. 1997;272(45):28210-28217. 208. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor a and g activators in a tissue-and inducer-specific manner. J Biol Chem. 1998;273(27):16710-16714. 209. Sato O, Kuriki C, Fukui Y, Motojima K. Dual pro- moter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor a and g ligands. J Biol Chem. 2002; 277(18):15703-15711. 210. Ramakrishnan SK, Khuder SS, Al-Share QY, Russo L, Abdallah SL, Patel PR, Heinrich G, Muturi HT, Mopidevi BR, Oyarce AM, Shah YM, Sanchez ER, Najjar SM. PPARa (peroxisome proliferator- activated receptor a) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition. J Biol Chem. 2016;291(15):8121-8129. 211.
  102. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of the acyl-coenzyme A syn- thetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem. 1995;270(33):19269-19276. 212. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem. 2000;275(21):16390-16399. 213. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor a (PPARa). J Biol Chem. 1998;273(10): 5678-5684. 214. Knight BL, Hebbachi A, Hauton D, Brown AM, Wiggins D, Patel DD, Gibbons GF. A role for PPARa in the control of SREBP activity and lipid synthesis in the liver. Biochem J. 2005;389(Pt 2):413-421. 215. Poirier H, Niot I, Monnot MC, Braissant O, Meunier- Durmort C, Costet P, Pineau T, Wahli W, Willson TM, Besnard P. Differential involvement of peroxisome-proliferator-activated receptors a and d in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochem J. 2001; 355(Pt 2):481-488. 216. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic ef- fects of peroxisome proliferators. Mol Cell Biol. 1995; 15(6):3012-3022. 217. Hughes ML, Liu B, Halls ML, Wagstaff KM, Patil R, Velkov T, Jans DA, Bunnett NW, Scanlon MJ, Porter CJ. Fatty acid-binding proteins 1 and 2 differentially modulate the activation of peroxisome proliferator- activated receptor a in a ligand-selective manner. J Biol Chem. 2015;290(22):13895-13906. 218. Sandberg MB, Bloksgaard M, Duran-Sandoval D, Duval C, Staels B, Mandrup S. The gene encoding acyl-CoA-binding protein is subject to metabolic regulation by both sterol regulatory element- binding protein and peroxisome proliferator- activated receptor a in hepatocytes. J Biol Chem. 2005;280(7):5258-5266. 219. Helledie T, Grøntved L, Jensen SS, Kiilerich P, Rietveld L, Albrektsen T, Boysen MS, Nøhr J, Larsen LK, Fleckner J, Stunnenberg HG, Kristiansen K, Mandrup S. The gene encoding the Acyl-CoA- binding protein is activated by peroxisome proliferator-activated receptor g through an intronic response element functionally conserved between humans and rodents. J Biol Chem. 2002; 277(30):26821-26830. 220. Louet JF, Chatelain F, Decaux JF, Park EA, Kohl C, Pineau T, Girard J, Pegorier JP. Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome- proliferator-activated receptor alpha (PPARa)-in- dependent pathway. Biochem J. 2001;354(Pt 1): 189-197. 221. Barrero MJ, Camarero N, Marrero PF, Haro D. Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator- activated receptor through a partially conserved peroxisome proliferator-responsive element. Bio- chem J. 2003;369(Pt 3):721-729. 222. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor a (PPARa) agonist treatment reverses PPARa dys- function and abnormalities in hepatic lipid meta- bolism in ethanol-fed mice. J Biol Chem. 2003; 278(30):27997-28004. 223.
  103. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regu- lates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA. 1994; 91(23):11012-11016. 224. Zhao Q, Yang R, Wang J, Hu DD, Li F. PPARa ac- tivation protects against cholestatic liver injury. Sci Rep. 2017;7(1):9967. 225. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor a (PPARa) in the cellular fasting response: the PPARa-null mouse as a model of fatty acid oxi- dation disorders. Proc Natl Acad Sci USA. 1999; 96(13):7473-7478. 226. Hashimoto T, Fujita T, Usuda N, Cook W, Qi C, Peters JM, Gonzalez FJ, Yeldandi AV, Rao MS, Reddy JK. Peroxisomal and mitochondrial fatty acid b-oxidation in mice nullizygous for both peroxi- some proliferator-activated receptor a and perox- isomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem. 1999;274(27): 19228-19236. 227. Djouadi F, Aubey F, Schlemmer D, Ruiter JP, Wanders RJ, Strauss AW, Bastin J. Bezafibrate in- creases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibro- blasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet. 2005;14(18): 2695-2703. 228. Yang Y, Feng Y, Zhang X, Nakajima T, Tanaka N, Sugiyama E, Kamijo Y, Aoyama T. Activation of PPARa by fatty acid accumulation enhances fatty acid degradation and sulfatide synthesis. Tohoku J Exp Med. 2016;240(2):113-122. 229. Mandard S, Müller M, Kersten S. Peroxisome proliferator-activated receptor a target genes. Cell Mol Life Sci. 2004;61(4):393-416. 230. Yamazaki K, Kuromitsu J, Tanaka I. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated re- ceptor a agonists. Biochem Biophys Res Commun. 2002;290(3):1114-1122. 231. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti JR Jr, Heyman RA. RXR agonists activate PPARa-in- ducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol. 1998; 18(2):272-276. 232. Zhang B, Marcus SL, Sajjadi FG, Alvares K, Reddy JK, Subramani S, Rachubinski RA, Capone JP. Identifi- cation of a peroxisome proliferator-responsive el- ement upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl- CoA dehydrogenase. Proc Natl Acad Sci USA. 1992;89(16):7541-7545. 233. Nicolas-Frances V, Dasari VK, Abruzzi E, Osumi T, Latruffe N. The peroxisome proliferator response element (PPRE) present at positions 2681/2669 in the rat liver 3-ketoacyl-CoA thiolase B gene func- tionally interacts differently with PPARa and HNF- 4. Biochem Biophys Res Commun. 2000;269(2): 347-351. 234. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, Zhou G. Differential gene regulation in human versus rodent hepato- cytes by peroxisome proliferator-activated receptor (PPAR) a. PPARa fails to induce peroxisome proliferation-associated genes in human cells in- dependently of the level of receptor expresson. J Biol Chem. 2001;276(34):31521-31527. 235. Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARa between mouse and human. PLoS One. 2009;4(8):e6796. 236. Shimizu M, Takeshita A, Tsukamoto T, Gonzalez FJ, Osumi T. Tissue-selective, bidirectional regulation of PEX11a and perilipin genes through a common peroxisome proliferator response element. Mol Cell Biol. 2004;24(3):1313-1323. 237. Li X, Baumgart E, Dong GX, Morrell JC, Jimenez- Sanchez G, Valle D, Smith KD, Gould SJ. PEX11a is required for peroxisome proliferation in response to 4-phenylbutyrate but is dispensable for peroxisome proliferator-activated receptor alpha-mediated per- oxisome proliferation. Mol Cell Biol. 2002;22(23): 8226-8240. 238. Johnson EF, Hsu MH, Savas U, Griffin KJ. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology. 2002;181-182: 203-206. 239.
  104. Kawashima H, Naganuma T, Kusunose E, Kono T, Yasumoto R, Sugimura K, Kishimoto T. Human fatty acid omega-hydroxylase, CYP4A11: determination of complete genomic sequence and characteriza- tion of purified recombinant protein. Arch Biochem Biophys. 2000;378(2):333-339. 240. Savas U, Machemer DE, Hsu MH, Gaynor P, Lasker JM, Tukey RH, Johnson EF. Opposing roles of per- oxisome proliferator-activated receptor a and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. J Biol Chem. 2009;284(24):16541-16552. 241. Le May C, Pineau T, Bigot K, Kohl C, Girard J, Pégorier JP. Reduced hepatic fatty acid oxidation in fasting PPARa null mice is due to impaired mi- tochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Lett. 2000;475(3):163-166. 242.
  105. Marrapodi M, Chiang JY. Peroxisome proliferator- activated receptor alpha (PPARa) and agonist in- hibit cholesterol 7a-hydroxylase gene (CYP7A1) transcription. J Lipid Res. 2000;41(4):514-520. 261. Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor- a-mediated downregulation of cholesterol 7a- hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21(11):1840- 1845. 262.
  106. Hunt MC, Yang YZ, Eggertsen G, Carneheim CM, Gåfvels M, Einarsson C, Alexson SE. The peroxisome proliferator-activated receptor a (PPARa) regulates bile acid biosynthesis. J Biol Chem. 2000;275(37): 28947-28953. 263.
  107. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol. 1995;15(1):351-357. 264. Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, Koenig W, März W, Tafuri S, Wahli W, Müller M, Kersten S. PPARa governs glycerol metabolism. J Clin Invest. 2004;114(1):94-103. 265. Sugden MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ. Peroxisome-proliferator-activated re- ceptor-a (PPARa) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem J. 2002;364(Pt 2): 361-368. 266. Motojima K, Seto K. Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase ki- nase 4 mRNA in the liver and muscles of mice. Biol Pharm Bull. 2003;26(7):954-958. 267.
  108. Mandard S, Stienstra R, Escher P, Tan NS, Kim I, Gonzalez FJ, Wahli W, Desvergne B, Müller M, Kersten S. Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. Cell Mol Life Sci. 2007;64(9):1145-1157. 268. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996; 15(19):5336-5348. 269. Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, Müller M, Kersten S. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ ANGPTL4) is present in blood plasma as a trun- cated protein that is increased by fenofibrate treatment. J Biol Chem. 2004;279(33):34411-34420. 270. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator- activated receptor target gene. J Biol Chem. 2000; 275(37):28488-28493. 271. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, Staels B. The nuclear receptors peroxisome proliferator-activated receptor a and Rev-erba mediate the species- specific regulation of apolipoprotein A-I expres- sion by fibrates. J Biol Chem. 1998;273(40): 25713-25720. 272.
  109. Holness MJ, Bulmer K, Gibbons GF, Sugden MC. Up- regulation of pyruvate dehydrogenase kinase iso- form 4 (PDK4) protein expression in oxidative skeletal muscle does not require the obligatory participation of peroxisome-proliferator-activated receptor alpha (PPARa). Biochem J. 2002; 366(Pt 3):839-846. 288. Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARa and PPARb: studies using null mice. Biochim Biophys Acta. 2003; 1632(1-3):80-89. 289. Colin S, Bourguignon E, Boullay AB, Tousaint JJ, Huet S, Caira F, Staels B, Lestavel S, Lobaccaro JM, Delerive P. Intestine-specific regulation of PPARa gene transcription by liver X receptors. Endocrinology. 2008;149(10):5128-5135. 290. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem. 1995;270(22):13470-13475. 291. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008;54(6):945-955. 292. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator- activated receptor alpha-inducible fatty acid oxi- dation determines the severity of hepatic steatosis in response to fasting. J Biol Chem. 2000;275(37): 28918-28928. 293.
  110. Rakhshandehroo M, Knoch B, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010;2010:612089. 294. Montagner A, Polizzi A, Fouché E, Ducheix S, Lippi Y, Lasserre F, Barquissau V, Régnier M, Lukowicz C, Benhamed F, Iroz A, Bertrand-Michel J, Al Saati T, Cano P, Mselli-Lakhal L, Mithieux G, Rajas F, Lagarrigue S, Pineau T, Loiseau N, Postic C, Langin D, Wahli W, Guillou H. Liver PPARa is crucial for whole-body fatty acid homeostasis and is pro- tective against NAFLD. Gut. 2016;65(7):1202-1214. 295. Maus M, Cuk M, Patel B, Lian J, Ouimet M, Kaufmann U, Yang J, Horvath R, Hornig-Do HT, Chrzanowska-Lightowlers ZM, Moore KJ, Cuervo AM, Feske S. Store-operated Ca 2+ entry controls induction of lipolysis and the transcriptional reprogramming to lipid metabolism. Cell Metab. 2017;25(3):698-712. 296. Rodr´ıguez JC, Gil-Gómez G, Hegardt FG, Haro D. Peroxisome proliferator-activated receptor medi- ates induction of the mitochondrial 3-hydroxy-3- methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem. 1994;269(29):18767-18772. 297. Pawlak M, Baugé E, Lalloyer F, Lefebvre P, Staels B. Ketone body therapy protects from lipotoxicity and acute liver failure upon Ppara deficiency. Mol Endocrinol. 2015;29(8):1134-1143. 298. Kim H, Mendez R, Zheng Z, Chang L, Cai J, Zhang R, Zhang K. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor a to regulate metabolic hormone FGF21. Endocrinology. 2014;155(3):769-782. 299. Kim H, Mendez R, Chen X, Fang D, Zhang K. Lysine acetylation of CREBH regulates fasting-induced hepatic lipid metabolism. Mol Cell Biol. 2015; 35(24):4121-4134. 300. Hebbachi AM, Knight BL, Wiggins D, Patel DD, Gibbons GF. Peroxisome proliferator-activated re- ceptor a deficiency abolishes the response of lipogenic gene expression to re-feeding: restoration of the normal response by activation of liver X receptor a. J Biol Chem. 2008;283(8):4866-4876. 301. Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl- CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochem J. 2004;378(Pt 3): 983-990. 302.
  111. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, Kelly CJ. Regulation of cytokine ex- pression by ligands of peroxisome proliferator acti- vated receptors. J Immunol. 2002;168(6):2795-2802. 397. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activa- tors as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90(6):703-710. 398. Dubrac S, Stoitzner P, Pirkebner D, Elentner A, Schoonjans K, Auwerx J, Saeland S, Hengster P, Fritsch P, Romani N, Schmuth M. Peroxisome proliferator-activated receptor-a activation inhibits Langerhans cell function. J Immunol. 2007;178(7): 4362-4372. 399. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999; 85(5):394-402. 400. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARa activators inhibit cytokine-induced vas- cular cell adhesion molecule-1 expression in hu- man endothelial cells. Circulation. 1999;99(24): 3125-3131. 401. Marx N, Mackman N, Schönbeck U, Yilmaz N, Hombach V, Libby P, Plutzky J. PPARa activators inhibit tissue factor expression and activity in hu- man monocytes. Circulation. 2001;103(2):213-219. 402. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPARa ag- onists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001; 103(2):207-212. 403. Mishra A, Chaudhary A, Sethi S. Oxidized omega-3 fatty acids inhibit NF-kB activation via a PPARa- dependent pathway. Arterioscler Thromb Vasc Biol. 2004;24(9):1621-1627. 404. Meissner M, Stein M, Urbich C, Reisinger K, Suske G, Staels B, Kaufmann R, Gille J. PPARa activators inhibit vascular endothelial growth factor receptor- 2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res. 2004;94(3): 324-332. 405. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkBa expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-a activators. J Biol Chem. 2000;275(47):36703-36707. 406.
  112. Delerive P, De Bosscher K, Vanden Berghe W, Fruchart J-C, Haegeman G, Staels B. DNA binding- independent induction of IkBa gene transcription by PPARa. Mol Endocrinol. 2002;16(5):1029-1039. 418.
  113. Stienstra R, Mandard S, Tan NS, Wahli W, Trautwein C, Richardson TA, Lichtenauer-Kaligis E, Kersten S, Müller M. The interleukin-1 receptor antagonist is a direct target gene of PPARa in liver. J Hepatol. 2007; 46(5):869-877. 419. Krönke G, Kadl A, Ikonomu E, Blüml S, Fürnkranz A, Sarembock IJ, Bochkov VN, Exner M, Binder BR, Leitinger N. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator- activated receptors. Arterioscler Thromb Vasc Biol. 2007;27(6):1276-1282. 420.
  114. Rommelaere S, Millet V, Gensollen T, Bourges C, Eeckhoute J, Hennuyer N, Baugé E, Chasson L, Cacciatore I, Staels B, Pitari G, Galland F, Naquet P. PPARa regulates the production of serum Vanin-1 by liver. FEBS Lett. 2013;587(22):3742-3748. 421. van Diepen JA, Jansen PA, Ballak DB, Hijmans A, Hooiveld GJ, Rommelaere S, Galland F, Naquet P, Rutjes FP, Mensink RP, Schrauwen P, Tack CJ, Netea MG, Kersten S, Schalkwijk J, Stienstra R. PPAR-a dependent regulation of vanin-1 mediates hepatic lipid metabolism. J Hepatol. 2014;61(2):366-372. 422. Staels B. PPAR agonists and the metabolic syn- drome. Therapie. 2007;62(4):319-326. 423. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23(7):351-363. 424. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS. Effects o fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther. 1998;36(6):345-349. 425. Krysiak R, Gdula-Dymek A, Okopien B. The effect of fenofibrate on lymphocyte release of proin- flammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances. Basic Clin Pharmacol Toxicol. 2013;112(3):198-202. 426. Toyoda T, Kamei Y, Kato H, Sugita S, Takeya M, Suganami T, Ogawa Y. Effect of peroxisome proliferator- activated receptor-a ligands in the interaction between adipocytes and macrophages in obese adipose tissue. Obesity (Silver Spring). 2008; 16(6): 1199-1207. 427. Poynter ME, Daynes RA. Age-associated alterations in splenic iNOS regulation: influence of constitu- tively expressed IFN-g and correction following supplementation with PPARa activators or vitamin E. Cell Immunol. 1999;195(2):127-136. 428. An HJ, Lee B, Kim SM, Kim DH, Chung KW, Ha SG, Park KC, Park YJ, Kim SJ, Yun HY, Chun P, Yu BP, Moon HR, Chung HY. A PPAR pan agonist, MHY2013 al- leviates age-related hepatic lipid accumulation by promoting fatty acid oxidation and suppressing in- flammation. Biol Pharm Bull. 2018;41(1):29-35. 429. Wu D, Sanin DE, Everts B, Chen Q, Qiu J, Buck MD, Patterson A, Smith AM, Chang CH, Liu Z, Artyomov MN, Pearce EL, Cella M, Pearce EJ. Type 1 interferons induce changes in core metabolism that are critical for immune function. Immunity. 2016;44(6):1325-1336. 430. Knoch B, Barnett MP, Cooney J, McNabb WC, Barraclough D, Laing W, Zhu S, Park ZA, Maclean P, Knowles SO, Roy NC. Molecular characterization of the onset and progression of colitis in inoculated interleukin-10 gene-deficient mice: a role for PPARa. PPAR Res. 2010;2010:621069. 431. Dreesen L, De Bosscher K, Grit G, Staels B, Lubberts E, Bauge E, Geldhof P. Giardia muris infection in mice is associated with a protective interleukin 17A response and induction of peroxisome proliferator-activated receptor a. Infect Immun. 2014;82(8):3333-3340. 432. Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, Lytle C, Straus DS. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology. 2007;133(1):108-123. 433. Mazzon E, Cuzzocrea S. Absence of functional peroxisome proliferator-activated receptor-alpha enhanced ileum permeability during experimental colitis. Shock. 2007;28(2):192-201. 434.
  115. Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta. 2007;1771(8):991-998. 435.
  116. Montaigne D, Marechal X, Modine T, Coisne A, Mouton S, Fayad G, Ninni S, Klein C, Ortmans S, Seunes C, Potelle C, Berthier A, Gheeraert C, Piveteau C, Deprez R, Eeckhoute J, Duez H, Lacroix D, Deprez B, Jegou B, Koussa M, Edme JL, Lefebvre P, Staels B. Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erba antagonism: a single-centre propensity-matched cohort study and a randomised study. Lancet. 2018;391(10115):59-69. 454. Durrington HJ, Farrow SN, Loudon AS, Ray DW. The circadian clock and asthma. Thorax. 2014;69(1): 90-92. 455. Gibbs JE, Ray DW. The role of the circadian clock in rheumatoid arthritis. Arthritis Res Ther. 2013;15(1):205.

Cited by

Sorted by citations

Authors
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K.
Affiliations
  • Ghent University (BE)
  • University of Manchester (GB)
  • Inserm (FR)
  • Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
Corresponding author
Staels, Bart
ORCID
Venue
Endocrine Reviews
Publisher
The Endocrine Society
Published
2018-07-17
Volume
39
Issue
5
Pages
760-802
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
DOI
10.1210/er.2018-00064
OpenAlex
W2883371150
Cited by
898
References
27
Citations by year
2026: 135 · 2025: 196 · 2024: 162 · 2023: 128 · 2022: 110 · 2021: 87 · 2020: 54 · 2019: 22 · 2018: 1 · 2013: 1
FWCI
4.02
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
Funders
  • FWO-Vlaanderen (G044317N)
  • Universiteit Gent (BE) (NURINFLAM)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
PPARα, nuclear receptors, lipid metabolism, inflammation, fibrates, PPARα agonist, drug-drug interactions, metabolic disorders, immune regulation, therapeutic target
MeSH terms
Animals, Humans, Inflammation, Liver, PPAR alpha, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review